Literature DB >> 20015987

Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes.

Catherine A Blish1, D Noah Sather, George Sellhorn, Leonidas Stamatatos, Yide Sun, Indresh Srivastava, Susan W Barnett, Brad Cleveland, Julie Overbaugh, Shiu-lok Hu.   

Abstract

Development of broadly cross-reactive neutralizing antibodies (NAbs) remains a major goal of HIV-1 vaccine development, but most candidate envelope immunogens have had limited ability to cross-neutralize heterologous strains. To evaluate the immunogenicity of subtype A variants of HIV-1, rabbits were immunized with pairs of closely related subtype A envelopes from the same individual. In each immunogen pair, one variant was readily neutralized by a variety of monoclonal antibodies and plasma antibodies, while the other was neutralization resistant, suggesting differences in the exposures of key epitopes. The breadth of the antibody response was evaluated against subtype A, B, C, and D variants of HIV-1. The specificity of the immunogen-derived neutralizing antibody response was also compared to that of the infected individuals from whom these variants were cloned. None of the immunogens produced broad neutralizing antibodies in immunized animals, and most of the neutralizing antibodies were directed to the variable loops, particularly the V3 loop. No detectable antibodies to either of the potentially exposed conserved epitopes, the membrane proximal external region, or the CD4 binding site were found with immunized rabbits. In contrast, relatively little of the neutralizing activity within the plasma samples of the infected individuals was directed to linear epitopes within the variable loops. These data indicate that immunogens designed to expose conserved regions did not enhance generation of broadly neutralizing antibodies in comparison with the immunogens that failed to expose those regions using this immunization approach.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20015987      PMCID: PMC2820908          DOI: 10.1128/JVI.01687-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  67 in total

1.  Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.

Authors:  Ming Li; Jesus F Salazar-Gonzalez; Cynthia A Derdeyn; Lynn Morris; Carolyn Williamson; James E Robinson; Julie M Decker; Yingying Li; Maria G Salazar; Victoria R Polonis; Koleka Mlisana; Salim Abdool Karim; Kunxue Hong; Kelli M Greene; Miroslawa Bilska; Jintao Zhou; Susan Allen; Elwyn Chomba; Joseph Mulenga; Cheswa Vwalika; Feng Gao; Ming Zhang; Bette T M Korber; Eric Hunter; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

2.  Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies.

Authors:  Brian Burke; Nina R Derby; Zane Kraft; Cheryl J Saunders; Chuanbin Dai; Nicholas Llewellyn; Irina Zharkikh; Lucia Vojtech; Tuofu Zhu; Indresh K Srivastava; Susan W Barnett; Leonidas Stamatatos
Journal:  Virology       Date:  2006-08-22       Impact factor: 3.616

3.  Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.

Authors:  Denise L Kothe; Julie M Decker; Yingying Li; Zhiping Weng; Frederic Bibollet-Ruche; Kenneth P Zammit; Maria G Salazar; Yalu Chen; Jesus F Salazar-Gonzalez; Zina Moldoveanu; Jiri Mestecky; Feng Gao; Barton F Haynes; George M Shaw; Mark Muldoon; Bette T M Korber; Beatrice H Hahn
Journal:  Virology       Date:  2006-11-13       Impact factor: 3.616

4.  Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity.

Authors:  Barna Dey; Marie Pancera; Krisha Svehla; Yuuei Shu; Shi-Hua Xiang; Jeffrey Vainshtein; Yuxing Li; Joseph Sodroski; Peter D Kwong; John R Mascola; Richard Wyatt
Journal:  J Virol       Date:  2007-03-14       Impact factor: 5.103

5.  HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.

Authors:  Catherine A Blish; Rebecca Nedellec; Kishorchandra Mandaliya; Donald E Mosier; Julie Overbaugh
Journal:  AIDS       Date:  2007-03-30       Impact factor: 4.177

6.  Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy.

Authors:  Mansun Law; Rosa M F Cardoso; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

7.  A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.

Authors:  Simon Beddows; Michael Franti; Antu K Dey; Marc Kirschner; Sai Prasad N Iyer; Danielle C Fisch; Thomas Ketas; Eloisa Yuste; Ronald C Desrosiers; Per Johan Klasse; Paul J Maddon; William C Olson; John P Moore
Journal:  Virology       Date:  2006-11-28       Impact factor: 3.616

8.  Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120.

Authors:  S Gnanakaran; Dorothy Lang; Marcus Daniels; Tanmoy Bhattacharya; Cynthia A Derdeyn; Bette Korber
Journal:  J Virol       Date:  2006-12-13       Impact factor: 5.103

9.  Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization.

Authors:  Peng Fei Zhang; Fatim Cham; Ming Dong; Anil Choudhary; Peter Bouma; Zhiqiang Zhang; Yiming Shao; Yan-Ru Feng; Lemin Wang; Nathalie Mathy; Gerald Voss; Christopher C Broder; Gerald V Quinnan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-31       Impact factor: 11.205

10.  Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B.

Authors:  Elin Solomonovna Gray; Tammy Meyers; Glenda Gray; David Charles Montefiori; Lynn Morris
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

View more
  17 in total

1.  Hyperimmune bovine colostrum as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 envelope with potential use in microbicides.

Authors:  Marit Kramski; Rob J Center; Adam K Wheatley; Jonathan C Jacobson; Marina R Alexander; Grant Rawlin; Damian F J Purcell
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

Review 2.  Neutralizing antibodies and control of HIV: moves and countermoves.

Authors:  Ann J Hessell; Nancy L Haigwood
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

Review 3.  Structure-based vaccine design in HIV: blind men and the elephant?

Authors:  Robert Pejchal; Ian A Wilson
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

4.  Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16.

Authors:  Thaddeus M Davenport; Della Friend; Katharine Ellingson; Hengyu Xu; Zachary Caldwell; George Sellhorn; Zane Kraft; Roland K Strong; Leonidas Stamatatos
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

5.  The role of amino acid changes in the human immunodeficiency virus type 1 transmembrane domain in antibody binding and neutralization.

Authors:  Erica Lovelace; Hengyu Xu; Catherine A Blish; Roland Strong; Julie Overbaugh
Journal:  Virology       Date:  2011-10-24       Impact factor: 3.616

6.  Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies.

Authors:  Delphine C Malherbe; Nicole A Doria-Rose; Lynda Misher; Travis Beckett; Wendy Blay Puryear; Jason T Schuman; Zane Kraft; Jean O'Malley; Motomi Mori; Indresh Srivastava; Susan Barnett; Leonidas Stamatatos; Nancy L Haigwood
Journal:  J Virol       Date:  2011-03-23       Impact factor: 5.103

7.  Improvement of antibody responses by HIV envelope DNA and protein co-immunization.

Authors:  Franco Pissani; Delphine C Malherbe; Jason T Schuman; Harlan Robins; Byung S Park; Shelly J Krebs; Susan W Barnett; Nancy L Haigwood
Journal:  Vaccine       Date:  2013-11-23       Impact factor: 3.641

8.  Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.

Authors:  Delphine C Malherbe; Franco Pissani; D Noah Sather; Biwei Guo; Shilpi Pandey; William F Sutton; Andrew B Stuart; Harlan Robins; Byung Park; Shelly J Krebs; Jason T Schuman; Spyros Kalams; Ann J Hessell; Nancy L Haigwood
Journal:  J Virol       Date:  2014-09-10       Impact factor: 5.103

9.  Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.

Authors:  Ann J Hessell; Delphine C Malherbe; Franco Pissani; Sean McBurney; Shelly J Krebs; Michelle Gomes; Shilpi Pandey; William F Sutton; Benjamin J Burwitz; Matthew Gray; Harlan Robins; Byung S Park; Jonah B Sacha; Celia C LaBranche; Deborah H Fuller; David C Montefiori; Leonidas Stamatatos; D Noah Sather; Nancy L Haigwood
Journal:  J Immunol       Date:  2016-03-04       Impact factor: 5.422

Review 10.  HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies.

Authors:  Steven W de Taeye; John P Moore; Rogier W Sanders
Journal:  Trends Immunol       Date:  2016-02-09       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.